The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.
A long-term finasteride user experienced side effects like sexual dysfunction, dry eyes, muscle weakness, and brain fog, which improved when they stopped the medication. They decided to stop finasteride again, questioning if maintaining hair was worth the negative impact on their well-being.
A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
A user has been taking finasteride 1mg for 10 years without side effects but is concerned about high estradiol levels affecting weight loss. Another user suggests using estradiol blockers under medical supervision to manage the levels.
The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.
The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.
A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.
A user is seeking recommendations for purchasing Minichek 5% solution, a PG-free minoxidil, due to a contact allergy to propylene glycol. They are looking for an affordable option comparable in price to Kirkland or Amazon brand minoxidil.
The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.
Finasteride is preferred over dutasteride due to its longer history, more research, and FDA approval, despite dutasteride being more potent. Users report varied side effects, influencing personal treatment choices.
User started using Pantostin Alfatradiol after watching haircafe on YouTube and noticed thicker hair. They wonder why it's not more popular, as it's a 5α-reductase inhibitor with a different mechanism than minoxidil.
The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.
OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.
User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
Finasteride and dutasteride are not considered safe during pregnancy, with some users suggesting caution and others sharing personal experiences of no issues. The general consensus is to avoid these medications during pregnancy to prevent any potential risks.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
Finasteride may affect prostate sensation and size, with some users reporting easier urination. Concerns exist about prostate shrinkage even at lower doses.
A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The conversation is about the safety and effects of using pyrilutamide for hair loss. One person reported severe negative effects, another experienced minor side effects without much benefit for hair, and a third found the anecdote helpful in making a decision.
The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.